Public Health Advisory: Cipro for Anthrax Exposure
Audience: Health professionals and general public
FDA reminds all health professionals and the general public that Cipro is approved for the inhaled form of anthrax after an individual has been exposed. Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established, except for use in inhalational anthrax (post-exposure). The FDA Center for Drug Evaluation and Research has posted a comprehensive web page on the use of Cipro for inhalational anthrax.